TECH Stock Recent News

Antwerp, April 22, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) invites its shareholders to participate in the Annual General Meeting, Special General Meeting & Extraordinary General Meeting that will be held on Thursday 22 May 2025 at 10.00 a.m. CET in 2000 Antwerp, De Gerlachekaai 20.

SCOTTSDALE, Ariz. , April 17, 2025 /PRNewswire/ -- Cyber Enviro-Tech, Inc. (OTCQB-CETI) today announced its successful registration with Kuwait Oil Company (KOC), the world's 10th largest oil producer.

Antwerp, April 14, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) has signed an agreement  with Fortescue to charter a new ammonia-powered vessel.   This emphasises the commitment of both companies to decarbonise the shipping industry. This 210,000-dwt ammonia-powered Newcastlemax will feature a dual fuel engine and is expected to be delivered by the end of 2026.

Bio-Techne (TECH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Antwerp, April 10, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) published its annual report in accordance with Belgian law for the year ended on 31 December 2024 on the Company's website in the “Investors” section under “Annual and financial reports”.

MINNEAPOLIS , April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope™ Multiomic LS Assay and protease-free workflows on Leica's BOND RX research staining instrument, further advancing the capabilities of spatial biology research.

TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.

CMB.TECH ANNOUNCES FINAL YEAR RESULTS TRANSFORMATIONAL YEAR AND STRONG EARNINGS ANTWERP, Belgium, 27 March 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) reported its final financial results today for the full year ended 31 December 2024. HIGHLIGHTS 2024 Profit of USD 93.1 million in Q4 2024 bringing full year profit to USD 870.8 million​ Total contract backlog increased to USD 2.94 billion Name change from Euronav to CMB.TECH (ticker symbol CMBT) CMB.TECH focused on its fleet rejuvenation with 21 newbuild deliveries Further fleet expansion with 1 container vessel, 2 dry bulk carriers, 2 product tankers, 6 chemical tankers and 2 CTVs contracted in 2024 & Q1 2025 Sale of 6 older Suezmaxes, 4 older VLCCs and 1 container vessel New hydrogen engine R&D Center in Japan Sale of Euronav Ship Management Hellas (ESMH) to Anglo- Eastern Univan Group HIGHLIGHTS Q1 2025 CMB.TECH joins forces with MOL to jointly own and charter a total of 9

MINNEAPOLIS , March 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region and support the company's long-term regional growth strategy. The new Customer Experience Centre is scheduled to open in summer 2026 and will feature a state-of-the-art Demonstration Laboratory hosting Bio-Techne's full instrument portfolio, including: The recently launched Leo™ System, powered by Simple Western™ Technology, which offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.

MINNEAPOLIS , March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA.